- Home
- GEHC vs TAK Comparison
GEHC vs TAK Comparison
Compare GEHC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEHC
- TAK
- Stock Information
- Founded
- GEHC 1892
- TAK 1781
- Country
- GEHC United States
- TAK Japan
- Employees
- GEHC N/A
- TAK N/A
- Industry
- GEHC Computer Software: Prepackaged Software
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- GEHC Technology
- TAK Health Care
- Exchange
- GEHC Nasdaq
- TAK Nasdaq
- Market Cap
- GEHC 36.2B
- TAK 42.2B
- IPO Year
- GEHC N/A
- TAK N/A
- Fundamental
- Price
- GEHC $91.09
- TAK $14.07
- Analyst Decision
- GEHC Buy
- TAK
- Analyst Count
- GEHC 12
- TAK 0
- Target Price
- GEHC $97.67
- TAK N/A
- AVG Volume (30 Days)
- GEHC 2.8M
- TAK 1.8M
- Earning Date
- GEHC 02-13-2025
- TAK 01-30-2025
- Dividend Yield
- GEHC 0.15%
- TAK 3.63%
- EPS Growth
- GEHC 43.17
- TAK 15.39
- EPS
- GEHC 4.34
- TAK 0.83
- Revenue
- GEHC $19,672,000,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- GEHC $5.62
- TAK $7.80
- Revenue Next Year
- GEHC $4.70
- TAK $0.36
- P/E Ratio
- GEHC $20.99
- TAK $33.80
- Revenue Growth
- GEHC 0.61
- TAK 9.83
- 52 Week Low
- GEHC $74.51
- TAK $12.58
- 52 Week High
- GEHC $94.80
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- GEHC 59.40
- TAK 64.16
- Support Level
- GEHC $85.50
- TAK $13.66
- Resistance Level
- GEHC $93.26
- TAK $13.97
- Average True Range (ATR)
- GEHC 1.91
- TAK 0.13
- MACD
- GEHC 0.20
- TAK 0.06
- Stochastic Oscillator
- GEHC 60.11
- TAK 96.15
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.